Al-Nozha Omar, Abulkhair Ahmed, Hawsawi Amal, Sayed Sawsan, Alrowathi Khlood, Aldeeb Nawaf, Alghabban Hadel, Elmehallawy Ghaidaa, Iskandarani Dalya, Lhmdi Mohammed, Taha Inass
College of Medicine, Taibah University, Al-Madinah Al-Munawwarah, Saudi Arabia.
Ministry of Health, Al-Riyadh, Saudi Arabia.
J Med Life. 2024 Nov;17(11):994-999. doi: 10.25122/jml-2024-0371.
There is an increasing requirement for new therapeutic approaches to address lung inflammation caused by COVID-19. Recent evidence suggests that statins may reduce mortality in patients with respiratory infections. This study aimed to investigate the impact of statin use on COVID-19 outcomes among hospitalized patients at Ohud Hospital and King Salman Medical City (KSMC) in Madinah, Saudi Arabia. A retrospective cohort study was conducted, including 547 patients with confirmed COVID-19 diagnoses admitted between March 2020 and December 2022. Patients were classified into statin and non-statin users based on statin administration during hospitalization. Logistic regression analyses-including univariate, multivariate, and predictive stepwise models-were employed to assess associations between statin use and clinical factors. Among the 547 patients, 200 (36.5%) were prescribed statins upon admission. Statin users were predominantly men and older. The presence of low-density lipoprotein (LDL) levels ≥ 100 mg/dL, cardiovascular disease (CVD), and advanced age were identified as strong predictors of statin use, with odds ratios (ORs) of 11.1, 3.8, and 3.1, respectively. Furthermore, the odds of receiving statins were significantly higher in male patients, individuals with hypertension, those with HbA1c levels ≥ 8%, and patients with positive cultures and sensitivity results. Statin use was associated with an 18%% reduction in the risk of mortality, with an adjusted OR of 0.80 (95% CI, 0.30-2.32), and a 7% reduction in the risk of hospital stay > 10 days, although these findings did not reach statistical significance. Among patients with COVID-19, LDL ≥ 100 mg/dl, CVD, and patients older than 60 years were identified as strong predictors for statin prescription.
对于应对由COVID-19引起的肺部炎症，新的治疗方法的需求日益增加。最近的证据表明，他汀类药物可能降低呼吸道感染患者的死亡率。本研究旨在调查在沙特阿拉伯麦地那的奥胡德医院和国王萨勒曼医疗城（KSMC）住院的患者中，使用他汀类药物对COVID-19结局的影响。进行了一项回顾性队列研究，纳入了2020年3月至2022年12月期间确诊为COVID-19的547例患者。根据住院期间是否使用他汀类药物，将患者分为他汀类药物使用者和非使用者。采用逻辑回归分析，包括单变量、多变量和预测性逐步模型，来评估他汀类药物使用与临床因素之间的关联。在这547例患者中，200例（36.5%）入院时被开具了他汀类药物。他汀类药物使用者主要为男性且年龄较大。低密度脂蛋白（LDL）水平≥100mg/dL、心血管疾病（CVD）和高龄被确定为使用他汀类药物的强预测因素，比值比（OR）分别为11.1、3.8和3.1。此外，男性患者、高血压患者、糖化血红蛋白（HbA1c）水平≥8%的患者以及培养和药敏结果为阳性的患者使用他汀类药物的几率显著更高。使用他汀类药物与死亡风险降低18%相关，调整后的OR为0.80（95%CI，0.30 - 2.32），住院时间>10天的风险降低7%，尽管这些结果未达到统计学显著性。在COVID-19患者中，LDL≥100mg/dl、CVD以及年龄大于60岁的患者被确定为开具他汀类药物的强预测因素。
